跳至主要内容
临床试验/NCT04622462
NCT04622462招募中不适用

A Multi-Centre Prospective Community-Based Observational Study on Prediction of Malignant Progression of Clinically Suspicious Oral Lesions with STRATICYTE

Proteocyte Diagnostics Inc.3 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2015年3月12日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
3
主要终点
Malignant Transformation Rate: Dysplasia

研究概览

简要总结

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

详细描述

Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL) risk assessment for progression to cancer is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intra-observer variations, dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in the early diagnosis of invasive oral cancer, a prospective multi-center observational study was designed with specimens obtained from community-based practices.

Methods: Patients that qualify to enroll in the study will be assessed for both standard of care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and followed for up to 60 months (from initial biopsy) to determine the outcome of their oral lesion(s).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
15 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma

排除标准

  • Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy

结局指标

主要结局

Malignant Transformation Rate: Dysplasia

时间窗: 60 months

Cancer progression rate in patients with oral neoplasia with dysplasia and STRATICYTE Low-Risk or Elevated Risk

次要结局

  • Malignant Transformation Rate: No Dysplasia(60 months)
  • Recurrence Rate(60 months)

研究者

发起方
Proteocyte Diagnostics Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验